Purchase this article with an account.
Seok Jae Lee, Kang Yeun Pak, Sung Who Park, Ik Soo Byon, Ji Eun E Lee; Treat-and-Extend Regimen using Ranibizumab for Polypoidal Choroidal Vasculopathy: One Year Results. Invest. Ophthalmol. Vis. Sci. 2016;57(12):510.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Clinical efficacy of treat-and-extend regimen (TER) has been reported in patients with exudative age-related macular degeneration. However, the clinical outcomes of a TER to treat polypoidal choroidal vasculopathy (PCV) have not yet been reported. We performed retrospective review study to investigate the efficacy of TER using ranibizumab to treat PCV.
We retrospectively reviewed the medical records of patients with PCV who had been treated using a TER for 1 year. Primary outcome was the proportion of eyes that did not lose ≥ 3 best-corrected visual acuity (BCVA) lines. Secondary outcomes included BCVA, central subfield macular thickness (CSMT), the number of intravitreal injections, the number of recurrences, and the maximal treatment interval without recurrence.
The mean visual acuity improved from 0.69 ± 0.49 logMAR at baseline to 0.42 ± 0.37 logMAR at 3 months (P = 0.001), 0.40 ± 0.39 logMAR at 6 months (P = 0.001) and 0.33 ± 0.32 logMAR at 12 months (P < 0.001). The mean CSMT improved from 324.3 ± 90.7 µm at baseline to 236.4 ± 43.1 µm at 3 months (P < 0.001), 238.7 ± 77.6 µm at 6 months (P = 0.001), and 266.2 ± 99.3 µm at 12 months (P = 0.011). None of the subjects lost ≥ 3 lines, and 12 eyes (52.2%) gained ≥ 3 lines. The mean number of intravitreal injections was 7.4. The mean maximal treatment interval was 8.6 weeks. After the loading phase, 7 eyes (30.4%) showed no recurrence at treatment interval of 12 weeks. Six eyes (26.1%) demonstrated persistent disease activity for 12 months.
The TER effectively improved visual acuity in PCV while reducing the number of injections required.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only